Barclays
HRTX icon

Barclays’s Heron Therapeutics HRTX Stock Holding History

Barclays’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-200
Closed -$5K – 7142
2018
Q4 		$5K Sell
200
-39,800
-100% -$1.09M ﹤0.01% 6436
2018
Q3 		$1.27M Buy
40,000
+25,000
+167% +$931K ﹤0.01% 3401
2018
Q2 		$583K Sell
15,000
-82,800
-85% -$2.64M ﹤0.01% 3802
2018
Q1 		$2.7M Buy
+97,800
New +$2.22M ﹤0.01% 2177

Other funds holding HRTX

Tejara Capital
Tejara Capital London, United Kingdom $205M AUM 0.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $149M AUM 35.54% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Congress Park Capital
Congress Park Capital Saratoga Springs, New York $381M AUM 20.14% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Apeiron RIA
Apeiron RIA Dallas, Texas $440M AUM 15.34% 1-Year Est. Return

Barclays's HRTX Position: Q3 2026 in Review

Barclays increased its Heron Therapeutics (HRTX) stake by 241% in Q3 2026, buying an estimated $83.2K and bringing the position to 310,479 shares worth $97.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4317.

Barclays first reported a position in HRTX in Q2 2014 and has held it in 50 quarters since. The position peaked at $2.25M in Q1 2021. 87 funds tracked by Wall St. Rank hold HRTX as of Q3 2026.

  • Barclays held 310,479 shares of Heron Therapeutics worth $97.3K as of Q3 2026.
  • Barclays bought 219,457 Heron Therapeutics shares in Q3 2026, an estimated $83.2K.
  • Heron Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4317 holding.
  • Barclays first reported a position in Heron Therapeutics in Q2 2014 and has held it in 50 quarters since.
  • Barclays's Heron Therapeutics position peaked at $2.25M in Q1 2021.
  • 87 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.